STOCK MARKET BSE NSE

B.1.617.2 variant behind majority of breakthrough Covid infections in India: Study

Variants of concern B.1.617.2, and B.1.1.7 were responsible for cases surge in April-May in Delhi, were the predominant lineages among breakthrough infections.

Published: 03rd June 2021 05:51 PM  |   Last Updated: 03rd June 2021 05:51 PM   |  A+A-

coronavirus, PPE, COVID 19

Image used for representational purpose only

Express News Service

NEW DELHI: Majority of the breakthrough infections following vaccination with Covishield and Covaxin were caused by SARS CoV2 lineage B.1.617.2, which is a variant of concern (VoC), according to study based on the genomic analysis of vaccine breakthrough infections in collaboration with clinicians at the AIIMS, New Delhi.

The analysis included 63 cases of vaccine breakthrough infections in Delhi, out of which 36 patients received two doses, while 27 had received one dose of vaccine. Ten patients received Covishield while 53 received Covaxin.

“B.1.617.2 was found to be the predominant lineage with 23 samples (63.9%) out of which 12 were in fully vaccinated and 11 in partially vaccinated groups. Four samples with 11.1% and 1 sample with 2.8% were assigned the lineages B.1.617.1 and B.1.1.7 respectively,” according to the study in preprints.

The patients had a mean age of 37 (21-92), in which 41 were males and 22 were females. None of the patients had any comorbidities which could act as a predisposing factor for breakthrough infections. AIIMS collaborated with the CSIR Institute of Genomics and Integrative Biology (CSIR-IGIB) for the study.

Variants of concern B.1.617.2, first detected in India, and B.1.1.7, detected in Maharashtra, were responsible for cases surge in April-May 2021 in Delhi, were the predominant lineages among breakthrough infections.

ALSO READ | Covishield seen preventing severe Covid even in breakthrough infections, finds study

Of the breakthrough infection cases analysed, 10 patients (8 with double doses of vaccine and 2 with single vaccine dose) additionally had total Immunoglobulin G (IgG) antibodies assessed by Chemiluminescent Immunoassay (Siemens), of which 6 patients had IgG antibodies a month before the infection, while 4 had antibodies after the disease episode.

“While antibody levels for a subset of patients were available, they became infected nevertheless and presented to the emergency just like other patients, putting in doubt the protection offered and or clinical relevance of total IgG as a surrogate of Covid immunity,” the study noted.

Of the 63 cases of vaccine breakthrough infections, including 36 who received full doses, there are no reports of mortality even though almost all cases presented with high-grade unremitting fever for 5-7 days.

“Viral load at the time of diagnosis was high in all the patients irrespective of vaccination status or type of vaccine received. The initial course of disease with high-grade non-remitting fever lasted for five to seven days in the vaccinated group, similar to the clinical presentation in unvaccinated patients,” it further said.

The authors said the present report is unique in many aspects as this is one of the first reports of symptomatic vaccine breakthrough infections, and breakthrough infections in a tertiary care setting apart from being the earliest reports of breakthrough infections with BBV152/Covaxin and B.1.617.2 variant of SARS-CoV-2.



Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp